Intellia Therapeutics, Inc. (0JBU.L)
USD 6.17
(-11.96%)
USD 6.17
(-11.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 250.8 Million USD | -11.85% |
| 2022 | 284.53 Million USD | 11.92% |
| 2021 | 254.22 Million USD | 70.33% |
| 2020 | 149.25 Million USD | 131.76% |
| 2019 | 64.39 Million USD | -7.2% |
| 2018 | 69.39 Million USD | -8.25% |
| 2017 | 75.63 Million USD | -15.14% |
| 2016 | 89.13 Million USD | 502.94% |
| 2015 | 14.78 Million USD | 372.6% |
| 2014 | 3.12 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 220.47 Million USD | -1.33% |
| 2024 Q1 | 223.45 Million USD | -10.91% |
| 2023 Q3 | 205.93 Million USD | -5.69% |
| 2023 Q4 | 250.8 Million USD | 21.79% |
| 2023 FY | 250.8 Million USD | -11.85% |
| 2023 Q1 | 227.04 Million USD | -20.2% |
| 2023 Q2 | 218.35 Million USD | -3.83% |
| 2022 Q2 | 229.87 Million USD | -7.69% |
| 2022 Q1 | 249.03 Million USD | -2.04% |
| 2022 Q4 | 284.53 Million USD | 9.64% |
| 2022 FY | 284.53 Million USD | 11.92% |
| 2022 Q3 | 259.5 Million USD | 12.89% |
| 2021 Q2 | 177.43 Million USD | 3.75% |
| 2021 Q4 | 254.22 Million USD | 11.57% |
| 2021 Q1 | 171.01 Million USD | 14.58% |
| 2021 FY | 254.22 Million USD | 70.33% |
| 2021 Q3 | 227.86 Million USD | 28.42% |
| 2020 Q4 | 149.25 Million USD | 15.76% |
| 2020 FY | 149.25 Million USD | 131.76% |
| 2020 Q3 | 128.93 Million USD | -7.4% |
| 2020 Q2 | 139.24 Million USD | 107.85% |
| 2020 Q1 | 66.99 Million USD | 4.03% |
| 2019 Q1 | 80.02 Million USD | 15.32% |
| 2019 FY | 64.39 Million USD | -7.2% |
| 2019 Q4 | 64.39 Million USD | -9.28% |
| 2019 Q3 | 70.98 Million USD | -6.08% |
| 2019 Q2 | 75.57 Million USD | -5.56% |
| 2018 Q1 | 64.04 Million USD | -15.33% |
| 2018 FY | 69.39 Million USD | -8.25% |
| 2018 Q4 | 69.39 Million USD | 19.72% |
| 2018 Q3 | 57.96 Million USD | -4.1% |
| 2018 Q2 | 60.44 Million USD | -5.63% |
| 2017 Q4 | 75.63 Million USD | 3.16% |
| 2017 FY | 75.63 Million USD | -15.14% |
| 2017 Q1 | 79.38 Million USD | -10.94% |
| 2017 Q2 | 77.39 Million USD | -2.51% |
| 2017 Q3 | 73.32 Million USD | -5.26% |
| 2016 Q4 | 89.13 Million USD | 6.94% |
| 2016 FY | 89.13 Million USD | 502.94% |
| 2016 Q2 | 87.02 Million USD | -15.25% |
| 2016 Q3 | 83.34 Million USD | -4.23% |
| 2016 Q1 | 102.68 Million USD | 594.6% |
| 2015 Q2 | 10.8 Million USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 14.78 Million USD | 372.6% |
| 2015 Q4 | 14.78 Million USD | 42.28% |
| 2015 Q3 | 10.39 Million USD | -3.8% |
| 2014 FY | 3.12 Million USD | 0.0% |
| 2014 Q4 | 2.35 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 59.808% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -98.898% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 59.397% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 5.261% |
| bluebird bio, Inc. | 424.62 Million USD | 40.934% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -264.764% |
| Imunon, Inc. | 8.53 Million USD | -2840.158% |
| Editas Medicine, Inc. | 150.05 Million USD | -67.143% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.781% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 92.845% |
| Myriad Genetics, Inc. | 312.9 Million USD | 19.844% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 75.397% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 48.548% |
| Verastem, Inc. | 71.18 Million USD | -252.333% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.636% |
| Waters Corporation | 3.47 Billion USD | 92.786% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.517% |
| Biogen Inc. | 12.04 Billion USD | 97.918% |
| Nektar Therapeutics | 267.04 Million USD | 6.081% |
| Perrigo Company plc | 6.04 Billion USD | 95.848% |
| Dynavax Technologies Corporation | 375.02 Million USD | 33.122% |
| Illumina, Inc. | 4.36 Billion USD | 94.255% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -612.986% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -28.135% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 2.211% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -572.552% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 86.73% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -204.257% |
| Evolus, Inc. | 209.68 Million USD | -19.611% |
| Adicet Bio, Inc. | 37.12 Million USD | -575.668% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -523.497% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.471% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 62.044% |
| FibroGen, Inc. | 585.72 Million USD | 57.18% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 94.9% |
| OPKO Health, Inc. | 622.47 Million USD | 59.708% |
| Homology Medicines, Inc. | 118.53 Million USD | -111.593% |
| Geron Corporation | 146.12 Million USD | -71.637% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.808% |
| Exelixis, Inc. | 678.44 Million USD | 63.032% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1149.604% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1901.021% |
| Zoetis Inc. | 9.29 Billion USD | 97.302% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 36.865% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -410.021% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.13% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -417.717% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.366% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 89.572% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -118.451% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 84.795% |
| Blueprint Medicines Corporation | 918.64 Million USD | 72.698% |
| Insmed Incorporated | 1.66 Billion USD | 84.907% |
| TG Therapeutics, Inc. | 169.08 Million USD | -48.332% |
| Incyte Corporation | 1.59 Billion USD | 84.248% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 78.845% |